$MOH
MOLINA HEALTHCARE, INC. Stock $moh

$moh Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000117992924000089 Filed on April 25, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$9.880B	$9.931B	$8.149B
YoY Change	18.65%	21.87%	4.88%
Cost Of Revenue	$8.368B	$8.414B	$6.871B
YoY Change	18.9%	22.46%	4.69%
Gross Profit	$1.512B	$1.517B	$1.278B
YoY Change	17.3%	18.7%	5.88%
Gross Profit Margin	15.3%	15.28%	15.68%
Selling, General & Admin	$987.0M	$1.007B	$763.0M
YoY Change	25.41%	31.98%	-2.05%
% of Gross Profit	65.28%	66.38%	59.7%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$46.00M	$45.00M	$44.00M
YoY Change	9.52%	2.27%	10.0%
% of Gross Profit	3.04%	2.97%	3.44%
Operating Expenses	$1.076B	$1.090B	$807.0M
YoY Change	29.79%	35.07%	-1.47%
Operating Profit	$434.0M	$427.0M	$455.0M
YoY Change	-5.65%	-6.15%	22.31%
Interest Expense	-$28.00M	-$27.00M	$28.00M
YoY Change	3.7%	-196.43%	0.0%
% of Operating Profit	-6.45%	-6.32%	6.15%
Other Income/Expense, Net	-$28.00M	-$27.00M	-$28.00M
YoY Change	3.7%	-3.57%	0.0%
Pretax Income	$406.0M	$399.0M	$427.0M
YoY Change	-2.4%	-6.56%	24.13%
Income Tax	$105.0M	$98.00M	$106.0M
% Of Pretax Income	25.86%	24.56%	24.82%
Net Earnings	$301.0M	$301.0M	$321.0M
YoY Change	-2.59%	-6.23%	24.42%
Net Earnings / Revenue	3.05%	3.03%	3.94%
Basic Earnings Per Share	$5.18	$5.21	$5.58
Diluted Earnings Per Share	$5.17	$5.16	$5.52
COMMON SHARES
Basic Shares Outstanding	58.60M shares	58.40M shares	57.90M shares
Diluted Shares Outstanding	58.20M shares	58.30M shares	58.00M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.701B	$8.937B	$8.364B
YoY Change	-1.08%	6.85%	7.34%
Cash & Equivalents	$4.354B	$4.513B	$4.554B
Short-Term Investments	$4.347B	$4.424B	$3.810B
Other Short-Term Assets	$399.0M	$381.0M	$259.0M
YoY Change	53.46%	47.1%	30.81%
Inventory
Prepaid Expenses
Receivables	$3.231B	$3.350B	$2.536B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.33B	$12.67B	$11.16B
YoY Change	7.78%	13.52%	9.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$305.0M	$295.0M	$274.0M
YoY Change	7.02%	7.66%	-30.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$136.0M	$623.0M	$119.0M
YoY Change	-76.83%	423.53%	-34.25%
Total Long-Term Assets	$2.854B	$2.845B	$2.212B
YoY Change	28.56%	28.62%	-0.09%
TOTAL ASSETS
Total Short-Term Assets	$12.33B	$12.67B	$11.16B
Total Long-Term Assets	$2.854B	$2.845B	$2.212B
Total Assets	$15.19B	$15.51B	$13.37B
YoY Change	11.16%	16.02%	8.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$973.0M	$1.114B	$787.0M
YoY Change	13.54%	41.55%	-2.72%
Accrued Expenses
YoY Change
Deferred Revenue	$13.00M	$328.0M	$654.0M
YoY Change	-96.86%	-49.85%	3533.33%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.836B	$8.514B	$7.614B
YoY Change	3.97%	11.82%	8.14%
LONG-TERM LIABILITIES
Long-Term Debt	$2.181B	$2.382B	$2.177B
YoY Change	-8.4%	9.42%	0.14%
Other Long-Term Liabilities	$122.0M	$124.0M	$88.00M
YoY Change	0.0%	40.91%	-34.33%
Total Long-Term Liabilities	$2.303B	$2.506B	$2.265B
YoY Change	-7.99%	10.64%	-1.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.836B	$8.514B	$7.614B
Total Long-Term Liabilities	$2.303B	$2.506B	$2.265B
Total Liabilities	$10.34B	$11.02B	$10.08B
YoY Change	3.01%	9.29%	5.4%
SHAREHOLDERS EQUITY
Retained Earnings	$4.489B	$4.188B	$3.117B
YoY Change	31.03%	34.36%	17.31%
Common Stock	$439.0M	$390.0M	$296.0M
YoY Change	28.74%	31.76%	35.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.843B	$4.493B	$3.288B
YoY Change
Total Liabilities & Shareholders Equity	$15.19B	$15.51B	$13.37B
YoY Change	11.16%	16.02%	8.18%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$301.0M	$301.0M	$321.0M
YoY Change	-2.59%	-6.23%	24.42%
Depreciation, Depletion And Amortization	$46.00M	$45.00M	$44.00M
YoY Change	9.52%	2.27%	10.0%
Cash From Operating Activities	-$219.0M	$214.0M	$916.0M
YoY Change	-144.97%	-76.64%	152.34%
INVESTING ACTIVITIES
Capital Expenditures	$27.00M	$27.00M	$32.00M
YoY Change	-12.9%	-15.63%	39.13%
Acquisitions		$295.0M	$0.00
YoY Change
Other Investing Activities	$80.00M	-$461.0M	-$5.000M
YoY Change	-175.47%	9120.0%	-138.46%
Cash From Investing Activities	$53.00M	-$488.0M	-$302.0M
YoY Change	-138.69%	61.59%	-508.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.00M	-62.00M	-$65.00M
YoY Change	20.0%	-4.62%	-15.58%
NET CHANGE
Cash From Operating Activities	-219.0M	214.0M	$916.0M
Cash From Investing Activities	53.00M	-488.0M	-$302.0M
Cash From Financing Activities	12.00M	-62.00M	-$65.00M
Net Change In Cash	-154.0M	-336.0M	$549.0M
YoY Change	-142.78%	-161.2%	52.5%
FREE CASH FLOW
Cash From Operating Activities	-$219.0M	$214.0M	$916.0M
Capital Expenditures	$27.00M	$27.00M	$32.00M
Free Cash Flow	-$246.0M	$187.0M	$884.0M
YoY Change	-153.95%	-78.85%	160.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
CY2024Q1	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	297000000	usd
CY2023Q1	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	172000000	usd
CY2024Q1	us-gaap	Net Investment Income NetInvestmentIncome	108000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	71000000	usd
CY2024Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	22000000	usd
CY2023Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	21000000	usd
CY2024Q1	us-gaap	Revenues Revenues	9931000000	usd
CY2023Q1	us-gaap	Revenues Revenues	8149000000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8414000000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6871000000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	711000000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	591000000	usd
CY2024Q1	moh	Premium Tax Expenses PremiumTaxExpenses	297000000	usd
CY2023Q1	moh	Premium Tax Expenses PremiumTaxExpenses	172000000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	45000000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	44000000	usd
CY2024Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	38000000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	16000000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	9505000000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	7694000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	426000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	455000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	27000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	28000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	399000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	427000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	98000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	106000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	301000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	321000000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.21
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.58
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.52
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	301000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	321000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-5000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	46000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-2000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	11000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	35000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	298000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	356000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4513000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4848000000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4424000000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4259000000	usd
CY2024Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	3350000000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3104000000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	381000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	331000000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	12668000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	12542000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	295000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	270000000	usd
CY2024Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1927000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1449000000	usd
CY2024Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	261000000	usd
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	261000000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	228000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	227000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	134000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	143000000	usd
CY2024Q1	us-gaap	Assets Assets	15513000000	usd
CY2023Q4	us-gaap	Assets Assets	14892000000	usd
CY2024Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	4571000000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	4204000000	usd
CY2024Q1	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	2501000000	usd
CY2023Q4	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	2294000000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1114000000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1252000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	328000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	418000000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8514000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8168000000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2180000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2180000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	202000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	205000000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	124000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	124000000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	11020000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10677000000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58000000	shares
CY2024Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	390000000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	410000000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-85000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-82000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4188000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3887000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4493000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4215000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15513000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14892000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4215000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	301000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-20000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4493000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2964000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	321000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	35000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-32000000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3288000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	301000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	321000000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45000000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44000000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-26000000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1000000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	36000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25000000	usd
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2000000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	5000000	usd
CY2024Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	123000000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	234000000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8000000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7000000	usd
CY2024Q1	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	-24000000	usd
CY2023Q1	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	296000000	usd
CY2024Q1	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	183000000	usd
CY2023Q1	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	270000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-215000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-215000000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-90000000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	295000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	65000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	101000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	214000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	916000000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	380000000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	646000000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	211000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	371000000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	295000000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32000000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-3000000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-5000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-488000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-302000000	usd
CY2024Q1	moh	Common Stock Withheld To Settle Employee Tax Obligations CommonStockWithheldToSettleEmployeeTaxObligations	56000000	usd
CY2023Q1	moh	Common Stock Withheld To Settle Employee Tax Obligations CommonStockWithheldToSettleEmployeeTaxObligations	58000000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-6000000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-7000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-62000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-65000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-336000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	549000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4908000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4048000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4572000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4597000000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4513000000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4554000000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	59000000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	43000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4572000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4597000000	usd
CY2024Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	3350000000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3104000000	usd
CY2024Q1	moh	Medical Premiums Liability Medical Care Costs Threshold MedicalPremiumsLiabilityMedicalCareCostsThreshold	1443000000	usd
CY2023Q4	moh	Medical Premiums Liability Medical Care Costs Threshold MedicalPremiumsLiabilityMedicalCareCostsThreshold	1344000000	usd
CY2023Q4	moh	Percent Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold PercentDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold	0.85
CY2023Q4	moh	Percent Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold PercentDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold	0.85
CY2024Q1	moh	Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold	49000000	usd
CY2023Q4	moh	Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold	64000000	usd
CY2023Q4	moh	Percent Due To Government Agencies Medicare Medical Loss Ratio Of Marketplace PercentDueToGovernmentAgenciesMedicareMedicalLossRatioOfMarketplace	0.80
CY2024Q1	moh	Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing	91000000	usd
CY2023Q4	moh	Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing	66000000	usd
CY2024Q1	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable	-267000000	usd
CY2024Q1	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable	296000000	usd
CY2024Q1	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Net Receivable AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetReceivable	29000000	usd
CY2023Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable	-201000000	usd
CY2023Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable	241000000	usd
CY2023Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Net Receivable AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetReceivable	40000000	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div>
CY2024Q1	moh	Investments Maturity Period InvestmentsMaturityPeriod	P15Y
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58300000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58000000.0	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.21
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.58
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.52
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	301000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	321000000	usd
CY2023Q4	moh	Shares Outstanding Excluding Restricted Stock Awards SharesOutstandingExcludingRestrictedStockAwards	57800000	shares
CY2022Q4	moh	Shares Outstanding Excluding Restricted Stock Awards SharesOutstandingExcludingRestrictedStockAwards	57400000	shares
CY2024Q1	moh	Weighted Average Numberof Shares Share Based Compensation WeightedAverageNumberofSharesShareBasedCompensation	100000	shares
CY2023Q1	moh	Weighted Average Numberof Shares Share Based Compensation WeightedAverageNumberofSharesShareBasedCompensation	100000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57900000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57500000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	400000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	500000	shares
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	4424000000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	4259000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	4537000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	126000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	4424000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	4367000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	129000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	4259000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	634000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	625000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	2419000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2366000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	431000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	427000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	1053000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	1006000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	4537000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	4424000000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	188000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	118000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	23000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	253000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	2000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	10000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	750000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	7000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	482	position
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	2323000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	119000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	1228	position
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	386000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	3000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	258	position
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	2431000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	126000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	1261	position
CY2024Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	261000000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	197000000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	59000000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount	5000000	usd
CY2024Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,571 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div>
CY2024Q1	moh	Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount	3239000000	usd
CY2023Q4	moh	Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount	2901000000	usd
CY2024Q1	moh	Pharmacy Claims Payable PharmacyClaimsPayable	229000000	usd
CY2023Q4	moh	Pharmacy Claims Payable PharmacyClaimsPayable	202000000	usd
CY2024Q1	moh	Capitation Claims Payable CapitationClaimsPayable	152000000	usd
CY2023Q4	moh	Capitation Claims Payable CapitationClaimsPayable	100000000	usd
CY2024Q1	moh	Other Claims Payable OtherClaimsPayable	951000000	usd
CY2023Q4	moh	Other Claims Payable OtherClaimsPayable	1001000000	usd
CY2024Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	4571000000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	4204000000	usd
CY2024Q1	moh	Non Risk Provider Payable NonRiskProviderPayable	353000000	usd
CY2023Q4	moh	Non Risk Provider Payable NonRiskProviderPayable	481000000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	4204000000	usd
CY2024Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	8748000000	usd
CY2024Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-334000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	8414000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	5409000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	2879000000	usd
CY2024Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	8288000000	usd
CY2024Q1	moh	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments	391000000	usd
CY2024Q1	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	-150000000	usd
CY2024Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	4571000000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	3528000000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	7169000000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-298000000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	6871000000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	4487000000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	2358000000	usd
CY2023Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	6845000000	usd
CY2023Q1	moh	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments	0	usd
CY2023Q1	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	270000000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	3824000000	usd
CY2024Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-334000000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-298000000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	20000000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	20000000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2180000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2180000000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2024Q1	us-gaap	Revenues Revenues	9931000000	usd
CY2023Q1	us-gaap	Revenues Revenues	8149000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	426000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	455000000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27000000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	399000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	427000000	usd
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001179929-24-000089-index-headers.html	Edgar Link	pending
0001179929-24-000089-index.html	Edgar Link	pending
0001179929-24-000089.txt	Edgar Link	pending
0001179929-24-000089-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
moh-20240331.htm	Edgar Link	pending
moh-20240331.xsd	Edgar Link	pending
moh-20240331_g1.jpg	Edgar Link	pending
moh1q24_ex311.htm	Edgar Link	pending
moh1q24_ex312.htm	Edgar Link	pending
moh1q24_ex321.htm	Edgar Link	pending
moh1q24_ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
moh-20240331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
moh-20240331_def.xml	Edgar Link	unprocessable
moh-20240331_lab.xml	Edgar Link	unprocessable
moh-20240331_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
moh-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MOH
MOLINA HEALTHCARE, INC. Stock $moh

2024 Q2 Form 10-Q Financial Statement

#000117992924000089 Filed on April 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MOH MOLINA HEALTHCARE, INC. Stock $moh

2024 Q2 Form 10-Q Financial Statement

#000117992924000089 Filed on April 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MOH
MOLINA HEALTHCARE, INC. Stock $moh